EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 2.0

Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia

Sheeja T Pullarkat, Vinod Pullarkat, Steven H Kroft, Carla S Wilson, Arshad N Ahsanuddin, Karen P Mann, Maung Thein, Wayne W Grody, Russell K Brynes

Journal of Hematopathology · 2009-03 · 2 (1)

DOI: 10.1007/s12308-009-0023-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hematopathology, online erschienen am 10.02.2009. Verfasst von Sheeja T Pullarkat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS, A7-149, Los Angeles, CA, 90095-…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 2.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although KIT mutations are present in 20-25% of cases of t(8;21)(q22;q22) acute myeloid leukemia (AML), concurrent development of systemic mastocytosis (SM) is exceedingly rare. We examined the clinicopathologic features of SM associated with t(8;21)(q22;q22) AML in ten patients (six from our institutions and four from published literature) with t(8;21) AML and SM. In the majority of these cases, a definitive diagnosis of SM was made after chemotherapy, when the mast cell infiltrates were prominent. Deletion 9q was an additional cytogenetic abnormality in four cases. Four of the ten patients failed to achieve remission after standard chemotherapy and seven of the ten patients have died of AML. In the two patients who achieved durable remission after allogeneic hematopoietic stem cell transplant, recipient-derived neoplastic bone marrow mast cells persisted despite leukemic remission. SM associated with t(8;21) AML carries a dismal prognosis; therefore, detection of concurrent SM at diagnosis of t(8;21) AML has important prognostic implications.

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, CHS, A7-149, Los Angeles, CA, 90095-1732, USA, spullarkat@mednet.ucla.edu.

Zitieren

APA

Pullarkat, S. T., Pullarkat, V., Kroft, S. H., Wilson, C. S., Ahsanuddin, A. N., Mann, K. P., Thein, M., Grody, W. W., & Brynes, R. K. (2009). Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. Journal of Hematopathology, 2(1). https://doi.org/10.1007/s12308-009-0023-2

Vancouver

Pullarkat ST, Pullarkat V, Kroft SH, Wilson CS, Ahsanuddin AN, Mann KP, et al. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. Journal of Hematopathology. 2009;2(1). doi:10.1007/s12308-009-0023-2

BibTeX
@article{Pullarkat2009,
  author = {Pullarkat, Sheeja T and Pullarkat, Vinod and Kroft, Steven H and Wilson, Carla S and Ahsanuddin, Arshad N and Mann, Karen P and Thein, Maung and Grody, Wayne W and Brynes, Russell K},
  title = {Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia},
  journal = {Journal of Hematopathology},
  year = {2009},
  volume = {2},
  number = {1},
  doi = {10.1007/s12308-009-0023-2}
}
Kostenlos starten →